

DAFTAR PUSTAKA

- Al Rajhi, Ali; Ambrus, Andte; Lastra, Rachel; Lum, flora C. 2018. Dry Eye Syndrome Preferred Practice Pattern. American Academy of Ophthalmology.
- Ambroziak, A.M., Szaflik, J., Szaflik, J.P., Ambroziak, M., Witkiewicz, J., Skopiński, P., 2016. Immunomodulation on the ocular surface: A review. *Cent. Eur. J. Immunol.* 41, 195–208. <https://doi.org/10.5114/ceji.2016.60995>
- Ames, Philip; Galor, Anat (2015). *Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence. Clinical Investigation*, 5(3), 267–285. doi:10.4155/cli.14.135
- Ang, B., Sng, J. J., Wang, P., Htoon, H. M., & Tong, L. 2017. Natrium Hyaluronate in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-Analysis. *Scientific reports*, 7(1), 9013. <https://doi.org/10.1038/s41598-017-08534-5>
- Asbell, PA, Fahim, MM, Haji, S, Koonapareddy, CV, Fan, VC 2006, Fluorophotometry as a diagnostic tool for the evaluation of dry eye disease, <https://bmcophthalmol.biomedcentral.com/articles/10.1186/1471-2415-6-20>
- Ayaki, M., Kawashima, M., Uchino, M., Tsubota, K., Negishi, K., 2018. Gender differences in adolescent dry eye disease: a health problem in girls. *Int. J. Ophthalmol.* 11, 301–307. <https://doi.org/10.18240/ijo.2018.02.20>
- Baiula, Monica; Spampinato, Santi. 2021. Experimental Pharmacotherapy for Dry Eye Disease : A Review. *J Exp Pharmacol.*
- Bascones-Martinez, A., Mattila, R., Gomez-Font, R., Meurman, J.H., 2014. Immunomodulatory drugs: Oral and systemic adverse effects. *Med. Oral Patol. Oral Cirugia Bucal* 19. <https://doi.org/10.4317/medoral.19087>
- Baudouin, C., Irkeç, M., Messmer, E.M., Benítez-del-Castillo, J.M., Bonini, S., Figueiredo, F.C., Geerling, G., Labetoulle, M., Lemp, M., Rolando, M., Van Setten, G., Aragona, P., 2018. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. *Acta Ophthalmol. (Copenh.)* 96, 111–119. <https://doi.org/10.1111/aos.13436>
- Benítez-Del-Castillo, J., Labetoulle, M., Baudouin, C., Rolando, M., Akova, Y.A., Aragona, P., Geerling, G., Merayo-Llodes, J., Messmer, E.M., Boboridis, K., 2017. Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting. *Ocul. Surf.* 15, 169–178. <https://doi.org/10.1016/j.jtos.2016.11.003>
- Bron AJ, Benjamin L, Snibson GR. Meibomian gland disease. classification and grading of lid changes. *Eye.* 1991;5:395–411.
- Byun, Yeo-jue; Kim, Tae-im; Kwon, Sang Min; Seo, Kyung Yul; Kim, Sun Woong; Kim, Eung Kweon; Park, Woo Chan (2012). *Efficacy of Combined 0.05% Cyclosporine and 1% Methylprednisolone Treatment for Chronic Dry Eye. Cornea*, 31(5), 509–513. doi:10.1097/ico.0b013e31818c69ef

- Chauhan, S.K., Dana, R., (2009). Role of Th17 cells in the immunopathogenesis of dry eye disease. *Mucosal Immunol.* 2, 375–376. <https://doi.org/10.1038/mi.2009.21>
- Chen Y, Chauhan SK, Saban DR, et al. Interferon- γ -secreting NK cells promote induction of dry eye disease. *J Leukoc Biol.* 2011;89:965-72.
- Chen, Y., Shao, C., Fan, N.-W., Nakao, T., Amouzegar, A., Chauhan, S.K., Dana, R., 2021. The functions of IL-23 and IL-2 on driving autoimmune effector T-helper 17 cells into the memory pool in dry eye disease. *Mucosal Immunol.* 14, 177–186. <https://doi.org/10.1038/s41385-020-0289-3>
- Chotikavanich, Suksri; de Paiva, Cintia S.; Li, De Quan; Chen, Joseph J.; Bian, Fang; Farley, William J.; Pflugfelder, Stephen C. (2009). *Production and Activity of Matrix Metalloproteinase-9 on the Ocular Surface Increase in Dysfunctional Tear Syndrome. Investigative Ophthalmology & Visual Science, 50(7), 3203–.* doi:10.1167/iovs.08-2476
- Cocho, L., Fernández, I., Calonge, M., Martínez, V., González-García, M.J., Caballero, D., López-Corral, L., García-Vázquez, C., Vázquez, L., Stern, M.E., Enríquez-de-Salamanca, A., 2016. Biomarkers in Ocular Chronic Graft Versus Host Disease: Tear Cytokine- and Chemokine-Based Predictive Model. *Invest. Ophthalmol. Vis. Sci.* 57, 746–758. <https://doi.org/10.1167/iovs.15-18615>
- Craig, J.P., Nichols, K.K., Akpek, E.K., Caffery, B., Dua, H.S., Joo, C.K., Liu, Z., Nelson, J.D., Nichols, J.J., Tsubota, K., Stapleton, F., 2017. TFOS DEWS II Definition and Classification Report. *Ocul. Surf.* 15, 276–283. <https://doi.org/10.1016/j.jtos.2017.05.008>
- Daull P, Lallemand F, Philips B, et al. (2011): Distribution of cyclosporin A in ocular tissues after topical administration of cyclosporin A-cationic emulsion to pigmented rabbits. *IOVS*; 186: 376
- De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. *Mucosal Immunol.* 2009;2:243-53.
- DEWS (2007) The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). *Ocular Surface*, 5, 75-92. [https://doi.org/10.1016/S1542-0124\(12\)70081-2](https://doi.org/10.1016/S1542-0124(12)70081-2)
- Djalilian, A.R., Pedram, H., Pflugfelder, S.C., 2005. Dry Eye. In: Krachmer, Mannis, Holland, editors. *Cornea*. Philadelphia: Elsevier, 1, pp. 521- 538.
- El AJ, Chauhan SK, Ecoiffier T, et al. Characterization of effector T cells in dry eye disease. *Invest Ophthalmol Vis Sci.* 2009;50:3802-7.
- Foulks D.N., Lemp M.A., Vester J.V., 2007. Report of the international dry eye workshop (DEWS). *The Ocular Surface*. Vol. 38(5):pp 62-204.
- Gayton, J.L., 2009. Etiology, prevalence, and treatment of dry eye disease. *Clin. Ophthalmol.* 3, 405–412. <https://doi.org/10.2147/opth.s5555>
- Ghoreschi, K.; Jesson, M. I.; Li, X.; Lee, J. L.; Ghosh, S.; Alsup, J. W.; Warner, J. D.; Tanaka, M.; Steward-Tharp, S. M.; Gadina, M.; Thomas, C. J.; Minnerly, J. C.; Storer, C. E.; LaBranche, T. P.; Radi, Z. A.; Dowty, M. E.; Head, R. D.; Meyer, D. M.; Kishore, N.; O'Shea, J. J. (2011). *Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-*

- 690,550). *The Journal of Immunology*, 186(7), 4234–4243. doi:10.4049/jimmunol.1003668
- Gündüz, K., Ozdemir, O., 1994. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome. *Acta Ophthalmol. (Copenh.)* 72, 438–442. <https://doi.org/10.1111/j.1755-3768.1994.tb02792.x>
- Hamrah P, Liu Y, Zhang Q, et al. Alterations in corneal stromal dendritic cell phenotype and distribution in inflammation. *Arch Ophthalmol.* 2003;121:1132-40.
- Heidari, M., Noorizadeh, F., Wu, K., Inomata, T., Mashaghi, A., 2019. Dry Eye Disease: Emerging Approaches to Disease Analysis and Therapy. *J. Clin. Med.* 8, 1439. <https://doi.org/10.3390/jcm8091439>
- Iskandar, Ferdy. 2020. “Diquafosol Tetranatrium: Tatalaksana Terkini untuk Dry Eye Disease (DED)?” 47 (7): 5.
- Jain, A.K., Sukhija, J., Dwedi, S., Sood, A., 2007. Effect of topical cyclosporine on tear functions in tear-deficient dry eyes. *Ann. Ophthalmol. Skokie Ill* 39, 19–25. <https://doi.org/10.1007/BF02697322>
- Johnson GL, Nakamura K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. *Biochim Biophys Acta.* 2007;1773:1341-8.
- Kaercher, T., Bron, A., 2008. Classification and Diagnosis of Dry Eye: Surgery for the dry eye. *Development in Ophthalmology*, 41, pp. 36.
- Kang, Min-Ji; Kim, Youn-Hee; Chou, Miyoung; Hwang, Jehyung; Cheon, Eun-Jeong; Lee, Hyun-Jung; Chung, So-Hyang (2019). *Evaluation of the Efficacy and Safety of A Novel 0.05% Cyclosporin A Topical Nanoemulsion in Primary Sjögren's Syndrome Dry Eye. Ocular Immunology and Inflammation*, (), 1–9. doi:10.1080/09273948.2019.1587470
- Kaswan RL (1988): Intraocular penetration of topically applied cyclosporin. *Transplantation Proceedings* 20 (suppl.): 650-655
- Khanal S., Tomlinson A., Esakowitz L., Bhatt P., Jones D., Nabili S., Mukerji S., 2008. Changes in corneal sensitivity and tear physiology after phacoemulsification. *Ophthal. Physiol. Opt.* 2008, vol 28. pp 127-34.
- Kim, K.W., Han, S.B., Han, E.R., Woo, S.J., Lee, J.J., Yoon, J.C., Hyon, J.Y., 2011. Association between depression and dry eye disease in an elderly population. *Invest. Ophthalmol. Vis. Sci.* 52, 7954–7958. <https://doi.org/10.1167/iovs.11-8050>
- Kim HY, Lee JE, Oh HN, Song JW, Han SY, Lee JS. Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction. *Int J Ophthalmol.* 2018 Apr 18;11(4):593-600. doi: 10.18240/ijo.2018.04.09. PMID: 29675376; PMCID: PMC5902362.
- Kojima, T., Nagata, T., Kudo, H., Müller-Lierheim, W., van Setten, G. B., Dogru, M., & Tsubota, K. (2020). The Effects of High Molecular Weight Hyaluronic Acid Eye Drop Application in Environmental Dry Eye Stress Model Mice. *International journal of molecular sciences*, 21(10), 3516. <https://doi.org/10.3390/ijms21103516>


- Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. *Arch Ophthalmol*. 2000;118:1489-96
- Lallemand F, Felt-Baeyens O, Besseghir K, et al. (2003): Cyclosporin A delivery to the eye: a pharmaceutical challenge. *Eur J Pharmaceutics Biopharmaceutics* 56: 307-318
- Lam H, Bleiden L, de Paiva CS, Farley W, Stern ME, Pflugfelder SC (2009) Tear cytokine profiles in dysfunctional tear syndrome. *Am J Ophthalmol* 147(2):198.e191–205.e191.
- Lee, B.S., Kabat, A.G., Bacharach, J., Karpecki, P., Luchs, J., 2020. Managing dry eye disease and facilitating realistic patient expectations: A review and appraisal of current therapies. *Clin. Ophthalmol.* 14, 119–126. <https://doi.org/10.2147/OPTH.S228838>
- Lee, S.Y., Han, S.J., Nam, S.M., Yoon, S.C., Ahn, J.M., Kim, T.-I., Kim, E.K., Seo, K.Y., 2013. Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients. *Am. J. Ophthalmol.* 156, 247–253.e1. <https://doi.org/10.1016/j.ajo.2013.04.003>
- Lee AJ, Lee J, Saw S, Gazzard G, Koh D, Widjaja D, et al. 2002. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. *Br J Ophthalmol.* 86: 1347–1351.
- Liu R., Gao C., Chen H., Li Y., Jin Y., Qi H. Analysis of Th17-associated cytokines and clinical correlations in patients with dry eye disease. *PLoS ONE*. 2017;12:e0173301. doi: 10.1371/journal.pone.0173301
- Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. *Invest Ophthalmol Vis Sci*. 2004;45:4293-4301
- Matossian, C., McDonald, M., Donaldson, K.E., Nichols, K.K., MacIver, S., Gupta, P.K., 2019. Dry Eye Disease: Consideration for Women’s Health. *J. Womens Health* 28, 502–514. <https://doi.org/10.1089/jwh.2018.7041>
- Massingale, M.L., Li, X., Vallabhajosyula, M., Chen, D., Wei, Y., Asbell, P.A., 2009. Analysis of inflammatory cytokines in the tears of dry eye patients. *Cornea* 28, 1023–1027. <https://doi.org/10.1097/ICO.0b013e3181a16578>
- Messmer EM (2015) The pathophysiology, diagnosis, and treatment of dry eye disease. *Dtsch Arztebl Int* 112(5):71–81.
- Messmer, Elisabeth M, Jan P Hoops, and Anselm Kampik. 2005. “Bilateral Recurrent Calcareous Degeneration of the Cornea.” *Cornea* 24 (4): 498–502. <https://doi.org/10.1097/01.icc.0000151559.32613.0b>.
- Mrugacz, M., Ostrowska, L., Bryl, A., Szulc, A., Zelazowska-Rutkowska, B., Mrugacz, G., 2017. Pro-inflammatory cytokines associated with clinical severity of dry eye disease of patients with depression. *Adv. Med. Sci.* 62, 338–344. <https://doi.org/10.1016/j.advms.2017.03.003>
- Nair, S., Vanathi, M., Mahapatra, M., Seth, T., Kaur, J., Velpandian, T., Ravi, A., Titiyal, J.S., Tandon, R., 2018. Tear inflammatory mediators and protein in eyes of post allogeneic hematopoietic stem cell transplant patients. *Ocul. Surf.* 16, 352–367. <https://doi.org/10.1016/j.jtos.2018.04.007>

- Nelson, J.D., 2006. In- Office Diagnostic Test for Dry Eye Disease. In: Asbel, P.A., Lemp, M.A., eds. *Dry Eye Disease: The Clinician's Guide to Diagnosis and Treatment*. New York: Thieme, 1, pp. 33-46.
- Nelson, J. Daniel, Jennifer P. Craig, Esen K. Akpek, Dimitri T. Azar, Carlos Belmonte, Anthony J. Bron, Janine A. Clayton, et al. 2017. "TFOS DEWS II Introduction." *The Ocular Surface* 15 (3): 269–75. <https://doi.org/10.1016/j.jtos.2017.05.005>.
- Niederhorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjogren's syndrome-like lacrimal keratoconjunctivitis. *J Immunol*. 2006;176:3950-7.
- Prabhasawat, P., Tesavibul, N., Mahawong, W., 2012. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. *Cornea* 31, 1386–1393. <https://doi.org/10.1097/ICO.0b013e31823cc098>
- Patel, S & Blades, K 2003, *Dry eye: a practical approach*, Elsevier Science Limited, London.
- Pearlman E, Johnson A, Adhikary G, et al. Toll-like receptors at the ocular surface. *Ocul Surf*. 2008;6:108-16..
- Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D (1999) Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca. *Curr Eye Res* 19(3):201–211
- Pflugfelder SC, Tseng S, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. *Cornea*. 1998;17:38–56.
- Pflugfelder, Stephen C.; de Paiva, Cintia S. (2017). *The Pathophysiology of Dry Eye Disease*. *Ophthalmology*, 124(11), S4–S13. doi:10.1016/j.ophtha.2017.07.010
- Roda, M., Corazza, I., Bacchi Reggiani, M.L., Pellegrini, M., Taroni, L., Giannaccare, G., Versura, P., 2020. Dry Eye Disease and Tear Cytokine Levels—A Meta-Analysis. *Int. J. Mol. Sci.* 21, 3111. <https://doi.org/10.3390/ijms21093111>
- Rodriguez-Martinez S, Cancino-Diaz ME, Jimenez-Zamudio L, et al. TLRs and NODs mRNA expression pattern in healthy mouse eye. *Br J Ophthalmol*. 2005;89:904-10.
- Rossi, G.C.M., 2011. How to Diagnose The Ocular Surface Disease in Treated Glaucoma Patients. *European Ophthalmic review*, 5(1), pp.38- 42.
- Sall, K., Stevenson, O.D., Mundorf, T.K., Reis, B.L., 2000. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. *Ophthalmology* 107, 631–639. [https://doi.org/10.1016/s0161-6420\(99\)00176-1](https://doi.org/10.1016/s0161-6420(99)00176-1)
- Schiffman, Rhett M. 2000. "Reliability and Validity of the Ocular Surface Disease Index." *Archives of Ophthalmology* 118 (5): 615. <https://doi.org/10.1001/archoph.118.5.615>.
- Shanti, Y., Shehada, R., Bakkar, M.M., Qaddumi, J., 2020. Prevalence and associated risk factors of dry eye disease in 16 northern West bank towns in

- Palestine: A cross-sectional study. *BMC Ophthalmol.* 20, 1–8. <https://doi.org/10.1186/s12886-019-1290-z>
- Shimazaki, Jun. 2018. “Definition and Diagnostic Criteria of Dry Eye Disease: Historical Overview and Future Directions.” *Investigative Ophthalmology & Visual Science* 59 (14): DES7. <https://doi.org/10.1167/iovs.17-23475>.
- Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. *Curr Top Microbiol Immunol.* 2006;311:17-58.
- Stern, M.E., Schaumburg, C.S., Pflugfelder, S.C., 2013. Dry eye as a mucosal autoimmune disease. *Int. Rev. Immunol.* 32, 19–41. <https://doi.org/10.3109/08830185.2012.748052>
- Stevenson, D., Tauber, J., Reis, B.L., 2000. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. *Ophthalmology* 107, 967–974. [https://doi.org/10.1016/s0161-6420\(00\)00035-x](https://doi.org/10.1016/s0161-6420(00)00035-x)
- Sun, Song; Tan, Xu-hua; Ren, Tian-li; et al. (2013). Clinical Analysis of Interleukin-6 Level in Tear and Serum of Dry Eye Patient. *Chinese Journal of Experimental Ophthalmology*.
- Syawal, SR. 2005. “Suatu Cakrawala Baru Patogenesis Dari Penanganan Sindrom ‘Dry Eye.’” *Jurnal Medika Nusantara Supplement.* 26: 84–87.
- Tanaka, T.; Kishimoto, T. (2014). The Biology and Medical Implications of Interleukin-6. *Cancer Immunology Research*, 2(4), 288–294. doi:10.1158/2326-6066.CIR-14-0022
- Tangmonkongvoragul, C., Chokesuwattanaskul, S., Khankaeo, C., Punyaseevee, R., Nakkara, L., Moolsan, S., Unruan, O., 2022. Prevalence of symptomatic dry eye disease with associated risk factors among medical students at Chiang Mai University due to increased screen time and stress during COVID-19 pandemic. *PLOS ONE* 17, e0265733. <https://doi.org/10.1371/journal.pone.0265733>
- Turner, Kathleen; Pflugfelder, Stephen C.; Ji, Zhonghua; Feuer, William J.; Stern, Michael; Reis, Brenda L. (2000). *Interleukin-6 Levels in the Conjunctival Epithelium of Patients with Dry Eye Disease Treated with Cyclosporine Ophthalmic Emulsion.* *Cornea*, 19(4), 492–496. doi:10.1097/00003226-200007000-00018
- Ueno H, Klechevsky E, Morita R, et al. Dendritic cell subsets in health and disease. *Immunol Rev.* 2007;219:118-42.
- Ulhaq, Zulvikar S; Soraya, Gita Vita; Budu; Wulandari, Lely Retno. (2020). The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis. *Nature.com : Scientific Reports* volume 10, Article number: 17453.
- Vroman DT, Sandoval HP, Fernandez de Castro LE, Kasper TJ, Holzer MP, Solomon KD (2005) Effect of hinge location on corneal sensation and dry eye after laser in situ keratomileusis for myopia. *J Cataract Refract Surg* 31:1881–1887
- Wang, MTM, AL Xue, and JP Craig. 2019. “Comparative Evaluation of 5 Validated Symptom Questionnaires as Screening Instruments for Dry Eye Disease.”

- JAMA Ophthalmology* 137 (2): 228–29.
<https://doi.org/10.1001/jamaophthalmol.2018.5243>.
- Wu, Xingdi., Chen, Xiang., Ma, Yajuan., Lin, Xueqi. 2020. Analysis of tear inflammatory molecules and clinical correlations in evaporative dry eye disease caused by meibomian gland dysfunction. *International Ophthalmology* volume 40, pages3049–3058.
- Yang, Guang; Wang, Ya Ming. 2021. Clinical Efficacy of Sodium Hyaluronate Eye Drops Combined With Pranoprofen in the Treatment of Patients with Dry Eye. *Indian J Pharm Sci* 2021:83(5) spl issue “1-5”.
- Yang, Y. J., Lee, W. Y., Kim, Y. J., & Hong, Y. P. (2021). A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome. *International journal of environmental research and public health*, 18(5), 2383. <https://doi.org/10.3390/ijerph18052383>
- Yokoi, Norihikom. *Tear film In : Basic and Clinical Perspective Dry Eye Syndrome*. Japan : Future Medicine Ltd. 2013. P 31-45
- Yoon KC, Jeong IY, Park YG, Yang SY (2007) Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. *Cornea* 26(4):431–437.

LAMPIRAN 1. SURAT PERSETUJUAN ETIK



REKOMENDASI PERSETUJUAN ETIK

Nomor : 11/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 10 Januari 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21120771	No Sponsor Protokol	
Peneliti Utama	dr. Desti Priani	Sponsor	
Judul Peneliti	Efektivitas Siklosporin-A Topikal 0,1% Dibanding Kombinasi Siklosporin-A Topikal 0,1% Dengan Sodium Hyaluronat Topikal Terhadap Penurunan Kadar Interleukin-6 Air Mata Pada Penderita Dry Eye Disease		
No Versi Protokol	2	Tanggal Versi	7 Januari 2022
No Versi PSP	2	Tanggal Versi	7 Januari 2022
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 5 Januari 2022	Masa Berlaku 10 Januari 2022 sampai 10 Januari 2023	Frekuensi review lanjutan
Ketua KEPK FKUH RSUH dan RSWs	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEPK FKUH RSUH dan RSWs	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

LAMPIRAN 2. FORMULIR PERSETUJUAN



KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
KOMITE ETIK PENELITIAN KESEHATAN
Fakultas Kedokteran Universitas Hasanuddin
RSPTN Universitas Hasanuddin
RSUP dr. Wahidin Sudirohusodo Makassar
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu FKUH
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10, MAKASSAR 90245
Contact Person: dr. Agussalim Bukhari, M.Med, Ph.D, Sp.GK 081241850858.
e-mail:agussalimbukhari@yahoo.com

Lampiran 2.

FORMULIR PERSETUJUAN

Saya yang bertanda tangan di bawah ini :

Nama : Umur : tahun
Alamat :
Telepon/HP :

Menyatakan bersedia untuk berpartisipasi pada penelitian ini yang berjudul :

**EFEKTIVITAS SIKLOSPORIN-A 0,1% TOPIKAL DIBANDINGKAN KOMBINASI
SIKLOSPORIN-A 0,1% TOPIKAL DENGAN SODIUM HYALURONAT TOPIKAL
TERHADAP PENURUNAN KADAR INTERLEUKIN-6 AIR MATA PADA PENDERITA
DRY EYE DISEASE**

setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan dan manfaat yang akan didapatkan pada penelitian ini, khususnya bagi kemajuan ilmu kedokteran.

Makassar,

Saksi I

Saksi II

(.....)

(.....)

Penanggung jawab penelitian :

dr. Desti Priani
Jl. Tanjung Pinang I No. 48 Bukit Baruga
Telp. 081243426387

Penanggung jawab medik :

dr. Hasnah Eka, Sp.M(K), M.Kes
Jl. Talasalapang Komp. Villa Taman Madani
Telp. 082188051024

DISETUJUI OLEH KOMISI PENELITIAN
KESEHATAN FAKULTAS KEDOKTERAN
UNHAS
TGL 10 JANUARI 2022

LAMPIRAN 3. FORM KUESIONER *DRY EYE*



KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI

KOMITE ETIK PENELITIAN KESEHATAN

Fakultas Kedokteran Universitas Hasanuddin

RSPTN Universitas Hasanuddin

RSUP dr. Wahidin Sudirohusodo Makassar

Sekretariat : Lantai 2 Gedung Laboratorium Terpadu FKUH

JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10, MAKASSAR 90245

Contact Person: dr. Agussalim Bukhari, M.Med, Ph.D, Sp.GK 081241850858

e-mail:agussalimbukhari@yahoo.com

KUESIONER *DRY EYE*

NAMA: _____

RM : _____

TGL LAHIR : ____/____/____

JENIS KELAMIN : Laki-laki Perempuan

PEKERJAAN : PNS Wiraswasta Lain-lain : _____

TINGKAT PENDIDIKAN TERAKHIR :

SD SMP SMA S1 S2 S3

SUKU : _____

RIWAYAT PENYAKIT SISTEMIK :

Diabetes Mellitus Hipertensi Lain-lain: _____

Kuesioner *Ocular Surface Disease Index (OSDI)*

Jawablah 12 pertanyaan berikut dengan melingkari angka di dalam table yang sesuai dengan jawaban anda.

Apakah anda mengalami kondisi sebagai berikut dalam 1 minggu terakhir?	Selalu sepanjang hari	Sebagian besar hari	Separuh hari	Kadang-kadang	Tidak pernah
1. Mata sensitif terhadap cahaya?	4	3	2	1	0
2. Mata terasa mengganjal atau berpasir?	4	3	2	1	0
3. Mata terasa nyeri?	4	3	2	1	0
4. Gangguan penglihatan ringan (penglihatan buram / kabur)?*	4	3	2	1	0
5. Gangguan penglihatan berat?*	4	3	2	1	0

Keterangan * : Gangguan penglihatan ditentukan menggunakan *reduced snellen eye chart* jarak 35 cm
 - Gangguan penglihatan ringan : Jika tajam penglihatan berkisar (20/40-20/60)
 - Gangguan penglihatan berat: Jika tajam penglihatan berkisar (3/60-6/60)

Subtotal skor untuk jawaban 1 – 5 (A)

Apakah anda memiliki kesulitan dalam melakukan hal-hal sebagai berikut dalam 1 minggu terakhir?	Selalu sepanjang hari	Sebagian besar hari	Separuh hari	Kadang-kadang	Tidak ada kesulitan	Tidak melakukan
6. Membaca?	4	3	2	1	0	N/A
7. Mengendarai kendaraan di malam hari?	4	3	2	1	0	N/A
8. Bekerja dengan computer atau menggunakan ATM (Anjungan Tunai Mandiri) bank?	4	3	2	1	0	N/A
9. Menonton televisi?	4	3	2	1	0	N/A

Subtotal skor untuk jawaban 6 – 9 (B)

Apakah anda pernah mengalami rasa tidak nyaman di mata saat berada pada kondisi sebagai berikut dalam 1 minggu terakhir?	Selalu sepanjang hari	Sebagian besar hari	Separuh hari	Kadang-kadang	Tidak pernah	Tidak melakukan
10. Kondisi berangin?	4	3	2	1	0	N/A
11. Tempat atau ruangan dengan kelembaban rendah (sangat kering)?*	4	3	2	1	0	N/A
12. Tempat dengan pendingin ruangan?	4	3	2	1	0	N/A

Keterangan * : Tempat atau ruangan dengan kelembaban rendah : Kelembaban lingkungan rendah dikaitkan jika sehari-hari tidak menggunakan AC (air conditioner).

Subtotal skor untuk jawaban 10 – 12 (C)

Jumlahkan subtotal A, B, dan C untuk mendapat nilai D

HASIL PEMERIKSAAN MATA

NAMA: _____





RM : _____

TGL LAHIR : ____ / ____ / ____
















Visus Oculus dexter :

Visus Oculus sinister :

PEMERIKSAAN SLITLAMP

OD	Slit Lamp	OS
Hiperemis (-); Edema (-); Benjolan (-)	Palpebra	Hiperemis (-), Edema (-), Benjolan (-)
Injeksi konjungtiva (-); Injeksi siliar (-); Sekret Mukoid (-); perdarahan (-)	Konjungtiva / Sklera	Injeksi konjungtiva (-); Injeksi siliar (-); Sekret (-); perdarahan (-)
Jernih 	Kornea	Jernih 
Dalam, jernih	BMD	Dalam, jernih
Coklat, kripte (+), sinekia anterior (-), sinekia posterior (-)	Iris	Coklat, kripte (+), sinekia anterior (-), sinekia posterior (-)
Bulat, refleks cahaya (+)	Pupil	Bulat, refleks cahaya (+)
	Lensa	
Tidak ada	Lokasi Kekeruhan	Tidak ada
Tidak ada	Tipe Katarak	Tidak ada

PEMERIKSAAN TERKAIT LAPISAN AIR MATA

	MATA KANAN	MATA KIRI														
<p align="center"><u>TBUT</u></p> <ul style="list-style-type: none"> - <u>Normal</u> : >10 detik - Mild dry <u>eye</u> : 7-10 detik - Moderate dry <u>eye</u> : 4-6 detik - Severe dry <u>eye</u> : ≤ 3 detik 																
<p align="center"><u>OCULAR STAINING</u></p> <ul style="list-style-type: none"> - Normal : Grade 0-1 - Mild dry eye : Grade I-II - Moderate dry eye : Grade II-III - Severe dry eye : Grade IV-V <table border="1"> <thead> <tr> <th>PANEL</th> <th>GRADE</th> </tr> </thead> <tbody> <tr> <td align="center">A </td> <td align="center">0</td> </tr> <tr> <td align="center">B </td> <td align="center">I</td> </tr> <tr> <td align="center">C </td> <td align="center">II</td> </tr> <tr> <td align="center">D </td> <td align="center">III</td> </tr> <tr> <td align="center">E </td> <td align="center">IV</td> </tr> <tr> <td align="center">>E</td> <td align="center">V</td> </tr> </tbody> </table>	PANEL	GRADE	A 	0	B 	I	C 	II	D 	III	E 	IV	>E	V		
PANEL	GRADE															
A 	0															
B 	I															
C 	II															
D 	III															
E 	IV															
>E	V															
<p align="center"><u>Schirmer Test</u></p> <ul style="list-style-type: none"> - <u>Normal</u> : 15 mm - Mild Dry <u>eye</u> : 9-14 mm. - Moderate Dry <u>eye</u> : 4 – 8 mm. - Severe Dry <u>eye</u> : < 4 mm. 																

LAMPIRAN 4. DATA SAMPEL PENELITIAN

No	Nama	Jenis Sampel	Usia	Jenis Kelamin	Skor OSDI		Visus		TBUT (detik)				Ocular Staining				Schirmer Tanpa Anestesi (mm)				Schirmer dengan Anestesi (mm)				Nilai Interleukin 6				Jenis Dry Eye berdasarkan TBUT				Jenis Dry Eye berdasarkan OSDI	
					Sebelum	Setelah	OD	OS	Sebelum		Setelah		Sebelum		Setelah		Sebelum		Setelah		Sebelum		Setelah		Sebelum		Setelah		Sebelum	Setelah				
									OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS	OD	OS						
1	Ny. W	Kombinasi terapi	48	Perempuan	81,25	10	20/50 F2	20/30 F2	3	3	10	7	Grade 3	Grade 3	Grade 1	Grade 1	35	21	15	7	1	6	15	10	88,1591	81,8349	84,8461	69,2055	severe	Severe	mild	mild	Severe	normal
2	Ny. D	Kombinasi terapi	31	Perempuan	41,67	13,63	20/30	20/30	4	2	9	6	Grade 1	Grade 3	Grade 0	Grade 2	15	9	17	20	12	7	6	10	77,3996	73,5734	66,8832	84,8461	moderate	severe	mild	moderate	Severe	mild
3	Tn. R	Monoterapi	36	Laki-laki	56,25	11,36	20/100	20/50	5	4	9	7	Grade 2	Grade 2	Grade 0	Grade 0	35	24	35	22	19	9	26	17	68,3266	48,7215	96,7496	54,1595	moderate	moderate	mild	mild	Severe	normal
4	Tn. R	Monoterapi	30	Laki-laki	43,75	18,18	Feb-60	Mar-60	3	3	4	5	Grade 2	Grade 2	Grade 1	Grade 0	13	15	11	14	6	7	5	6	60,0029	89,2615	43,4941	43,8719	severe	severe	moderate	moderate	Severe	mild
5	Tn. L	Monoterapi	38	Laki-laki	35,41	9,09	20/20	20/20	3	4	4	6	Grade 2	Grade 2	Grade 1	Grade 1	11	11	11	14	12	11	20	21	79,4025	70,9893	55,8978	64,9855	severe	moderate	moderate	moderate	Severe	normal
6	Ny. I	Monoterapi	35	Perempuan	43,18	13,63	20/80	20/60	5	4	6	7	Grade 2	Grade 2	Grade 1	Grade 1	18	16	20	18	20	16	15	16	78,5888	90,8803	60,2301	44,8286	moderate	moderate	moderate	mild	Severe	mild
7	Ny. WO	Monoterapi	51	Perempuan	45,45	6,81	20/60	20/30 F2	3	3	7	6	Grade 2	Grade 2	Grade 0	Grade 0	10	12	16	15	12	8	13	12	72,3531	58,8082	64,8055	51,7345	severe	Severe	mild	moderate	Severe	normal
8	Nn. NM	Kombinasi terapi	28	Perempuan	50	8,33	20/120	20/120	3	3	8	10	Grade 1	Grade 1	Grade 0	Grade 0	15	14	20	22	10	15	16	17	64,0857	52,5067	92,9932	78,9166	severe	Severe	mild	mild	Severe	normal
9	Ny. D	Kombinasi terapi	33	Perempuan	41,67	8,33	20/80	20/80	5	3	5	7	Grade 2	Grade 3	Grade 1	Grade 1	18	13	13	14	23	20	11	11	116,9949	138,5478	74,9281	78,1275	moderate	Severe	moderate	mild	Severe	normal
10	Nn. L	Kombinasi terapi	31	Perempuan	38,63	4,54	20/70 F1	20/200	4	3	12	7	Grade 1	Grade 1	Grade 0	Grade 0	11	18	14	20	14	19	13	11	98,9231	109,6429	69,4223	59,3935	moderate	Severe	normal	mild	Severe	normal
11	Tn. J	Monoterapi	47	Laki-laki	31,25	6,25	20/40 F1	20/50 F2	6	4	11	13	Grade 1	Grade 1	Grade 0	Grade 0	26	35	21	35	19	27	14	15	102,5509	128,1363	102,5013	71,0496	moderate	moderate	normal	normal	moderate	normal
12	Ny. NF	Kombinasi terapi	30	Perempuan	31,25	4,54	20/80	20/80	4	4	6	7	Grade 1	Grade 1	Grade 0	Grade 0	25	35	25	35	19	24	16	18	152,3298	124,473	102,3649	92,3294	moderate	moderate	moderate	mild	moderate	normal
13	Ny. N	Kombinasi terapi	41	Perempuan	60,41	10,41	20/400	20/400	6	5	10	12	Grade 1	Grade 1	Grade 0	Grade 0	35	33	21	26	15	28	16	17	64,2176	69,5668	52,2334	54,0524	moderate	moderate	mild	normal	Severe	normal
14	Ny. R	Kombinasi terapi	49	Perempuan	67,5	7,5	20/20	20/20	5	4	5	6	Grade 1	Grade 1	Grade 0	Grade 0	3	3	12	19	2	2	10	14	105,9295	93,6081	60,1703	65,8139	moderate	moderate	moderate	moderate	Severe	normal
15	Ny. IK	Monoterapi	33	Perempuan	39,58	4,16	20/30	20/25	5	4	8	12	Grade 1	Grade 1	Grade 0	Grade 0	10	16	10	12	7	8	12	14	89,7518	71,3271	90,6103	67,2439	moderate	moderate	mild	normal	Severe	normal
16	Nn. AV	Monoterapi	30	Perempuan	39,58	8,33	20/25	20/30	5	5	12	9	Grade 1	Grade 1	Grade 0	Grade 0	33	19	15	14	14	12	13	12	118,0007	103,6056	67,3642	59,4652	moderate	moderate	normal	mild	Severe	normal
17	Tn. AM	Monoterapi	67	Laki-laki	43,75	9,09	20/60 F	20/60	5	6	12	9	Grade 1	Grade 1	Grade 0	Grade 0	20	18	21	25	16	14	15	15	92,5014	88,0489	97,6383	123,4232	moderate	moderate	normal	mild	Severe	normal
18	Ny. NY	Monoterapi	52	Perempuan	37,5	6,25	20/40 F1	20/40 F2	3	3	7	10	Grade 1	Grade 1	Grade 0	Grade 0	11	21	11	10	15	10	15	10	68,5553	72,9691	61,8331	72,3289	severe	severe	mild	mild	Severe	normal
19	Ny. AB	Kombinasi terapi	71	Perempuan	40	8,33	20/70	20/50	5	4	8	9	Grade 2	Grade 2	Grade 0	Grade 0	13	3	16	17	9	2	9	10	122,7154	123,1451	69,9645	64,3615	moderate	moderate	mild	mild	severe	normal
20	Drop Out... Tidak datang kontrol																																	

LAMPIRAN 5. HASIL UJI STATISTIK

Frequency Table

			Gender			
Perlakuan			Frequency	Percent	Valid Percent	Cumulative Percent
Monoterapi	Valid	Laki-laki	6	60.0	60.0	60.0
		Perempuan	4	40.0	40.0	100.0
		Total	10	100.0	100.0	
Kombinasi terapi	Valid	Perempuan	9	100.0	100.0	100.0

			Riwayat_Penyakit			
Perlakuan			Frequency	Percent	Valid Percent	Cumulative Percent
Monoterapi	Valid	Tidak ada	9	90.0	90.0	90.0
		Ada	1	10.0	10.0	100.0
		Total	10	100.0	100.0	
Kombinasi terapi	Valid	Tidak ada	8	88.9	88.9	88.9
		Ada	1	11.1	11.1	100.0
		Total	9	100.0	100.0	

Ocular Staining OD_Sebelum

Perlakuan			Frequency	Percent	Valid Percent	Cumulative Percent
Monoterapi	Valid	Grade 1	5	50.0	50.0	50.0
		Grade 2	5	50.0	50.0	100.0
		Total	10	100.0	100.0	
Kombinasi terapi	Valid	Grade 1	6	66.7	66.7	66.7
		Grade 2	2	22.2	22.2	88.9
		Grade 3	1	11.1	11.1	100.0
		Total	9	100.0	100.0	

Ocular Staining OS_Sebelum

Perlakuan			Frequency	Percent	Valid Percent	Cumulative Percent
Monoterapi	Valid	Grade 1	5	50.0	50.0	50.0
		Grade 2	5	50.0	50.0	100.0
		Total	10	100.0	100.0	
Kombinasi terapi	Valid	Grade 1	5	55.6	55.6	55.6
		Grade 2	1	11.1	11.1	66.7
		Grade 3	3	33.3	33.3	100.0
		Total	9	100.0	100.0	

Ocular Staining OD_Sesudah

Perlakuan			Frequency	Percent	Valid Percent	Cumulative Percent
Monoterapi	Valid	Grade 0	7	70.0	70.0	70.0
		Grade 1	3	30.0	30.0	100.0
		Total	10	100.0	100.0	
Kombinasi terapi	Valid	Grade 0	7	77.8	77.8	77.8
		Grade 1	2	22.2	22.2	100.0
		Total	9	100.0	100.0	

Ocular Staining OS_Sesudah

Perlakuan			Frequency	Percent	Valid Percent	Cumulative Percent
Monoterapi	Valid	Grade 0	8	80.0	80.0	80.0
		Grade 1	2	20.0	20.0	100.0
		Total	10	100.0	100.0	
Kombinasi terapi	Valid	Grade 0	6	66.7	66.7	66.7
		Grade 1	2	22.2	22.2	88.9
		Grade 2	1	11.1	11.1	100.0
		Total	9	100.0	100.0	

Descriptives

Perlakuan			Statistic	Std. Error		
Usia	Monoterapi	Mean	43.2222	3.98531		
		95% Confidence Interval for Mean	Lower Bound 34.0321	Upper Bound 52.4124		
		5% Trimmed Mean	42.6358			
		Median	38.0000			
		Variance	142.944			
		Std. Deviation	1.19559E1			
		Minimum	30.00			
		Maximum	67.00			
		Range	37.00			
		Interquartile Range	17.50			
		Skewness	.958	.717		
		Kurtosis	.397	1.400		
		Kombinasi terapi	Kombinasi terapi	Mean	40.2222	4.65707
				95% Confidence Interval for Mean	Lower Bound 29.4830	Upper Bound 50.9614
5% Trimmed Mean	39.1914					
Median	33.0000					
Variance	195.194					
Std. Deviation	1.39712E1					
Minimum	28.00					
Maximum	71.00					
Range	43.00					
Interquartile Range	18.00					
Skewness	1.501			.717		
Kurtosis	2.159			1.400		
Skor_OSDI_Sebelum	Monoterapi			Mean	41.7911	2.37810
				Lower Bound	36.3072	

		95% Confidence Interval for Mean	Upper Bound	47.2750	
		5% Trimmed Mean		41.5735	
		Median		43.1800	
		Variance		50.898	
		Std. Deviation		7.13431	
		Minimum		31.25	
		Maximum		56.25	
		Range		25.00	
		Interquartile Range		8.15	
		Skewness		.694	.717
		Kurtosis		1.455	1.400
	Kombinasi terapi	Mean		50.2644	5.41368
		95% Confidence Interval for Mean	Lower Bound	37.7805	
			Upper Bound	62.7484	
		5% Trimmed Mean		49.5994	
		Median		41.6700	
		Variance		263.771	
		Std. Deviation		1.62410E1	
		Minimum		31.25	
		Maximum		81.25	
		Range		50.00	
		Interquartile Range		24.64	
		Skewness		.942	.717
		Kurtosis		.016	1.400
Skor_OSDI_Sesudah	Monoterapi	Mean		9.4244	1.45784
		95% Confidence Interval for Mean	Lower Bound	6.0627	
			Upper Bound	12.7862	
		5% Trimmed Mean		9.2305	
		Median		9.0900	
		Variance		19.128	
		Std. Deviation		4.37351	

		Minimum		4.16	
		Maximum		18.18	
		Range		14.02	
		Interquartile Range		6.25	
		Skewness		1.009	.717
		Kurtosis		.716	1.400
	Kombinasi terapi	Mean		8.4011	.94705
		95% Confidence Interval for Mean	Lower Bound	6.2172	
			Upper Bound	10.5850	
		5% Trimmed Mean		8.3251	
		Median		8.3300	
		Variance		8.072	
		Std. Deviation		2.84115	
		Minimum		4.54	
		Maximum		13.63	
		Range		9.09	
		Interquartile Range		4.19	
		Skewness		.275	.717
		Kurtosis		.425	1.400
VisusLogMAR_OD	Monoterapi	Mean		.3901	.07235
		95% Confidence Interval for Mean	Lower Bound	.2232	
			Upper Bound	.5569	
		5% Trimmed Mean		.3946	
		Median		.4771	
		Variance		.047	
		Std. Deviation		.21705	
		Minimum		.00	
		Maximum		.70	
		Range		.70	
		Interquartile Range		.30	
		Skewness		-.465	.717
		Kurtosis		-.146	1.400

Kombinasi terapi	Mean		.5495	.12287
	95% Confidence Interval for Mean	Lower Bound	.2662	
		Upper Bound	.8328	
	5% Trimmed Mean		.5383	
	Median		.5441	
	Variance		.136	
	Std. Deviation		.36862	
	Minimum		.00	
	Maximum		1.30	
	Range		1.30	
	Interquartile Range		.40	
	Skewness		.691	.717
	Kurtosis		1.709	1.400
	VisusLogMAR_OS Monoterapi	Mean		.2917
95% Confidence Interval for Mean		Lower Bound	.1619	
		Upper Bound	.4214	
5% Trimmed Mean			.2976	
Median			.3010	
Variance			.028	
Std. Deviation			.16879	
Minimum			.00	
Maximum			.48	
Range			.48	
Interquartile Range			.30	
Skewness			-.622	.717
Kurtosis			-.784	1.400
Kombinasi terapi		Mean		.5593
	95% Confidence Interval for Mean	Lower Bound	.2345	
		Upper Bound	.8841	
	5% Trimmed Mean		.5491	
	Median		.6021	
	Variance		.179	

		Std. Deviation		.42256	
		Minimum		.00	
		Maximum		1.30	
		Range		1.30	
		Interquartile Range		.71	
		Skewness		.453	.717
		Kurtosis		-.502	1.400
TBUT_OD_Sebelum	Monoterapi	Mean		4.2222	.40062
		95% Confidence	Lower Bound	3.2984	
		Interval for Mean	Upper Bound	5.1460	
		5% Trimmed Mean		4.1914	
		Median		5.0000	
		Variance		1.444	
		Std. Deviation		1.20185	
		Minimum		3.00	
		Maximum		6.00	
		Range		3.00	
		Interquartile Range		2.00	
		Skewness		.018	.717
		Kurtosis		-1.955	1.400
	Kombinasi terapi	Mean		4.3333	.33333
		95% Confidence	Lower Bound	3.5647	
		Interval for Mean	Upper Bound	5.1020	
		5% Trimmed Mean		4.3148	
		Median		4.0000	
		Variance		1.000	
		Std. Deviation		1.00000	
		Minimum		3.00	
		Maximum		6.00	
		Range		3.00	
		Interquartile Range		1.50	
		Skewness		.107	.717

		Kurtosis		-,643	1,400
TBUT_OS_Sebelum	Monoterapi	Mean		3,8889	,30932
		95% Confidence	Lower Bound	3,1756	
		Interval for Mean	Upper Bound	4,6022	
		5% Trimmed Mean		3,8210	
		Median		4,0000	
		Variance		,861	
		Std. Deviation		,92796	
		Minimum		3,00	
		Maximum		6,00	
		Range		3,00	
		Interquartile Range		1,00	
		Skewness		1,470	,717
		Kurtosis		3,281	1,400
		Kombinasi terapi		Mean	
95% Confidence	Lower Bound			2,7665	
Interval for Mean	Upper Bound			4,1223	
5% Trimmed Mean				3,4383	
Median				3,0000	
Variance				,778	
Std. Deviation				,88192	
Minimum				2,00	
Maximum				5,00	
Range				3,00	
Interquartile Range				1,00	
Skewness				,214	,717
Kurtosis				,144	1,400
TBUT_OD_Sesudah	Monoterapi			Mean	
		95% Confidence	Lower Bound	5,4118	
		Interval for Mean	Upper Bound	9,6993	
		5% Trimmed Mean		7,5062	
		Median		7,0000	

		Variance		7.778	
		Std. Deviation		2.78887	
		Minimum		4.00	
		Maximum		12.00	
		Range		8.00	
		Interquartile Range		5.00	
		Skewness		.280	.717
		Kurtosis		-.759	1.400
	Kombinasi terapi	Mean		8.1111	.80699
		95% Confidence Interval for Mean	Lower Bound	6.2502	
			Upper Bound	9.9720	
		5% Trimmed Mean		8.0679	
		Median		8.0000	
		Variance		5.861	
		Std. Deviation		2.42097	
		Minimum		5.00	
		Maximum		12.00	
		Range		7.00	
		Interquartile Range		4.50	
		Skewness		.038	.717
		Kurtosis		-.969	1.400
TBUT_OS_Sesudah	Monoterapi	Mean		8.3333	.94281
		95% Confidence Interval for Mean	Lower Bound	6.1592	
			Upper Bound	10.5075	
		5% Trimmed Mean		8.2593	
		Median		7.0000	
		Variance		8.000	
		Std. Deviation		2.82843	
		Minimum		5.00	
		Maximum		13.00	
		Range		8.00	
		Interquartile Range		5.00	

	Skewness		.630	.717	
	Kurtosis		-1.006	1.400	
Kombinasi terapi	Mean		7.8889	.67586	
	95% Confidence	Lower Bound	6.3303		
	Interval for Mean	Upper Bound	9.4474		
	5% Trimmed Mean		7.7654		
	Median		7.0000		
	Variance		4.111		
	Std. Deviation		2.02759		
	Minimum		6.00		
	Maximum		12.00		
	Range		6.00		
	Interquartile Range		3.00		
	Skewness		1.233	.717	
	Kurtosis		.738	1.400	
	Schirmer1OD_Sebelum Monoterapi	Mean		17.1111	2.88889
		95% Confidence	Lower Bound	10.4493	
Interval for Mean		Upper Bound	23.7729		
5% Trimmed Mean			16.5123		
Median			13.0000		
Variance			75.111		
Std. Deviation			8.66667		
Minimum			10.00		
Maximum			35.00		
Range			25.00		
Interquartile Range			12.50		
Skewness			1.285	.717	
Kurtosis			.979	1.400	
Kombinasi terapi		Mean		18.8889	3.60726
		95% Confidence	Lower Bound	10.5705	
	Interval for Mean	Upper Bound	27.2073		
	5% Trimmed Mean		18.8765		

	Median		15.0000	
	Variance		117.111	
	Std. Deviation		1.08218E1	
	Minimum		3.00	
	Maximum		35.00	
	Range		32.00	
	Interquartile Range		18.00	
	Skewness		.478	.717
	Kurtosis		-.560	1.400
Schirmer1OS_Sebelum Monoterapi	Mean		18.6667	2.44949
	95% Confidence	Lower Bound	13.0181	
	Interval for Mean	Upper Bound	24.3152	
	5% Trimmed Mean		18.1852	
	Median		16.0000	
	Variance		54.000	
	Std. Deviation		7.34847	
	Minimum		11.00	
	Maximum		35.00	
	Range		24.00	
	Interquartile Range		9.00	
	Skewness		1.493	.717
	Kurtosis		2.568	1.400
Kombinasi terapi	Mean		16.5556	3.86620
	95% Confidence	Lower Bound	7.6401	
	Interval for Mean	Upper Bound	25.4710	
	5% Trimmed Mean		16.2840	
	Median		14.0000	
	Variance		134.528	
	Std. Deviation		1.15986E1	
	Minimum		3.00	
	Maximum		35.00	
	Range		32.00	

	Interquartile Range		21.00	
	Skewness		.550	.717
	Kurtosis		-.720	1.400
Schirmer1OD_Sesudah Monoterapi	Mean		17.3333	2.69258
	95% Confidence	Lower Bound	11.1242	
	Interval for Mean	Upper Bound	23.5424	
	5% Trimmed Mean		16.7593	
	Median		16.0000	
	Variance		65.250	
	Std. Deviation		8.07775	
	Minimum		10.00	
	Maximum		35.00	
	Range		25.00	
	Interquartile Range		10.00	
	Skewness		1.364	.717
	Kurtosis		2.069	1.400
Kombinasi terapi	Mean		17.0000	1.41421
	95% Confidence	Lower Bound	13.7388	
	Interval for Mean	Upper Bound	20.2612	
	5% Trimmed Mean		16.8333	
	Median		16.0000	
	Variance		18.000	
	Std. Deviation		4.24264	
	Minimum		12.00	
	Maximum		25.00	
	Range		13.00	
	Interquartile Range		7.00	
	Skewness		.795	.717
	Kurtosis		-.097	1.400
Schirmer1OS_Sesudah Monoterapi	Mean		18.3333	2.61937
	95% Confidence	Lower Bound	12.2931	
	Interval for Mean	Upper Bound	24.3736	

	5% Trimmed Mean		17.8704	
	Median		15.0000	
	Variance		61.750	
	Std. Deviation		7.85812	
	Minimum		10.00	
	Maximum		35.00	
	Range		25.00	
	Interquartile Range		10.50	
	Skewness		1.306	.717
	Kurtosis		1.510	1.400
Kombinasi terapi	Mean		20.0000	2.58199
	95% Confidence	Lower Bound	14.0459	
	Interval for Mean	Upper Bound	25.9541	
	5% Trimmed Mean		19.8889	
	Median		20.0000	
	Variance		60.000	
	Std. Deviation		7.74597	
	Minimum		7.00	
	Maximum		35.00	
	Range		28.00	
	Interquartile Range		8.50	
	Skewness		.400	.717
	Kurtosis		1.521	1.400
Schirmer2OD_Sebelum Monoterapi	Mean		13.4444	1.76471
	95% Confidence	Lower Bound	9.3750	
	Interval for Mean	Upper Bound	17.5139	
	5% Trimmed Mean		13.4938	
	Median		12.0000	
	Variance		28.028	
	Std. Deviation		5.29413	
	Minimum		6.00	
	Maximum		20.00	

	Range		14.00		
	Interquartile Range		10.50		
	Skewness		-.093	.717	
	Kurtosis		-1.591	1.400	
Kombinasi terapi	Mean		11.6667	2.40370	
	95% Confidence	Lower Bound	6.1237		
	Interval for Mean	Upper Bound	17.2096		
	5% Trimmed Mean		11.6296		
	Median		12.0000		
	Variance		52.000		
	Std. Deviation		7.21110		
	Minimum		1.00		
	Maximum		23.00		
	Range		22.00		
	Interquartile Range		11.50		
	Skewness		-.103	.717	
	Kurtosis		-.482	1.400	
	Schirmer2OS_Sebelum Monoterapi	Mean		12.7778	2.09349
		95% Confidence	Lower Bound	7.9502	
Interval for Mean		Upper Bound	17.6054		
5% Trimmed Mean			12.3086		
Median			11.0000		
Variance			39.444		
Std. Deviation			6.28048		
Minimum			7.00		
Maximum			27.00		
Range			20.00		
Interquartile Range			7.50		
Skewness			1.591	.717	
Kurtosis			2.903	1.400	
Kombinasi terapi		Mean		13.6667	3.24465
			Lower Bound	6.1845	

	95% Confidence Interval for Mean	Upper Bound	21.1489	
	5% Trimmed Mean		13.5185	
	Median		15.0000	
	Variance		94.750	
	Std. Deviation		9.73396	
	Minimum		2.00	
	Maximum		28.00	
	Range		26.00	
	Interquartile Range		18.00	
	Skewness		.093	.717
	Kurtosis		-1.632	1.400
Schirmer2OD_Sesudah Monoterapi	Mean		14.3333	1.97906
	95% Confidence Interval for Mean	Lower Bound	9.7696	
		Upper Bound	18.8970	
	5% Trimmed Mean		14.2037	
	Median		14.0000	
	Variance		35.250	
	Std. Deviation		5.93717	
	Minimum		5.00	
	Maximum		26.00	
	Range		21.00	
	Interquartile Range		6.50	
	Skewness		.661	.717
	Kurtosis		1.363	1.400
Kombinasi terapi	Mean		12.4444	1.21462
	95% Confidence Interval for Mean	Lower Bound	9.6435	
		Upper Bound	15.2454	
	5% Trimmed Mean		12.6049	
	Median		13.0000	
	Variance		13.278	
	Std. Deviation		3.64387	

	Minimum		6.00	
	Maximum		16.00	
	Range		10.00	
	Interquartile Range		6.50	
	Skewness		-.579	.717
	Kurtosis		-.883	1.400
Schirmer2OS_Sesudah Monoterapi	Mean		14.0000	1.43372
	95% Confidence	Lower Bound	10.6938	
	Interval for Mean	Upper Bound	17.3062	
	5% Trimmed Mean		14.0556	
	Median		15.0000	
	Variance		18.500	
	Std. Deviation		4.30116	
	Minimum		6.00	
	Maximum		21.00	
	Range		15.00	
	Interquartile Range		5.50	
	Skewness		-.412	.717
	Kurtosis		.804	1.400
Kombinasi terapi	Mean		13.1111	1.13584
	95% Confidence	Lower Bound	10.4919	
	Interval for Mean	Upper Bound	15.7304	
	5% Trimmed Mean		13.0123	
	Median		11.0000	
	Variance		11.611	
	Std. Deviation		3.40751	
	Minimum		10.00	
	Maximum		18.00	
	Range		8.00	
	Interquartile Range		7.00	
	Skewness		.512	.717
	Kurtosis		-1.889	1.400

IL6OD_Sebelum	Monoterapi	Mean		79.1148	4.53510
		95% Confidence Interval for Mean	Lower Bound	68.6569	
			Upper Bound	89.5728	
		5% Trimmed Mean		78.8746	
		Median		78.5888	
		Variance		185.104	
		Std. Deviation		1.36053E1	
		Minimum		60.00	
		Maximum		102.55	
		Range		42.55	
		Interquartile Range		22.69	
		Skewness		.431	.717
		Kurtosis		-.599	1.400
		Kombinasi terapi		Mean	
95% Confidence Interval for Mean	Lower Bound			76.5768	
	Upper Bound			1.2137E2	
5% Trimmed Mean				97.9466	
Median				98.9231	
Variance				848.906	
Std. Deviation				2.91360E1	
Minimum				64.09	
Maximum				152.33	
Range				88.24	
Interquartile Range				49.05	
Skewness				.492	.717
Kurtosis				-.222	1.400
IL6OS_Sebelum	Monoterapi			Mean	
		95% Confidence Interval for Mean	Lower Bound	62.2520	
			Upper Bound	97.5574	
		5% Trimmed Mean		78.9576	
		Median		72.9691	
		Variance		527.406	

		Std. Deviation		2.29653E1	
		Minimum		48.72	
		Maximum		128.14	
		Range		79.41	
		Interquartile Range		25.17	
		Skewness		.975	.717
		Kurtosis		1.780	1.400
	Kombinasi terapi	Mean		96.3221	9.74878
		95% Confidence Interval for Mean	Lower Bound	73.8414	
			Upper Bound	1.1880E2	
		5% Trimmed Mean		96.4104	
		Median		93.6081	
		Variance		855.348	
		Std. Deviation		2.92463E1	
		Minimum		52.51	
		Maximum		138.55	
		Range		86.04	
		Interquartile Range		52.24	
		Skewness		.007	.717
		Kurtosis		-1.325	1.400
IL6OD_Sesudah	Monoterapi	Mean		74.8622	7.30138
		95% Confidence Interval for Mean	Lower Bound	58.0252	
			Upper Bound	91.6992	
		5% Trimmed Mean		75.0694	
		Median		64.8055	
		Variance		479.791	
		Std. Deviation		2.19041E1	
		Minimum		43.49	
		Maximum		102.50	
		Range		59.01	
		Interquartile Range		39.13	
		Skewness		.050	.717

		Kurtosis	-1.865	1.400	
Kombinasi terapi		Mean	74.8673	5.30981	
		95% Confidence	Lower Bound	62.6229	
		Interval for Mean	Upper Bound	87.1118	
		5% Trimmed Mean		74.5971	
		Median		69.9645	
		Variance		253.747	
		Std. Deviation		1.59294E1	
		Minimum		52.23	
		Maximum		102.36	
		Range		50.13	
		Interquartile Range		25.39	
		Skewness		.484	.717
		Kurtosis		-.394	1.400
	IL6OS_Sesudah	Monoterapi	Mean	65.9584	8.03389
95% Confidence			Lower Bound	47.4322	
Interval for Mean			Upper Bound	84.4846	
5% Trimmed Mean				63.9929	
Median				64.9855	
Variance				580.890	
Std. Deviation				2.41017E1	
Minimum				43.87	
Maximum				123.42	
Range				79.55	
Interquartile Range				23.41	
Skewness				1.899	.717
Kurtosis				4.482	1.400
Kombinasi terapi				Mean	71.8940
		95% Confidence	Lower Bound	62.2893	
		Interval for Mean	Upper Bound	81.4988	
		5% Trimmed Mean		71.7499	
		Median		69.2055	

Variance	156.132	
Std. Deviation	1.24953E1	
Minimum	54.05	
Maximum	92.33	
Range	38.28	
Interquartile Range	20.00	
Skewness	.246	.717
Kurtosis	-.870	1.400

Tests of Normality

		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Usia	Monoterapi	.224	9	.200 [*]	.904	9	.278
	Kombinasi terapi	.253	9	.101	.820	9	.035
Skor_OSDI_Sebelum	Monoterapi	.193	9	.200 [*]	.944	9	.626
	Kombinasi terapi	.257	9	.088	.902	9	.265
Skor_OSDI_Sesudah	Monoterapi	.197	9	.200 [*]	.922	9	.406
	Kombinasi terapi	.177	9	.200 [*]	.930	9	.482
VisusLogMAR_OD	Monoterapi	.211	9	.200 [*]	.959	9	.789
	Kombinasi terapi	.221	9	.200 [*]	.933	9	.511
VisusLogMAR_OS	Monoterapi	.189	9	.200 [*]	.918	9	.374
	Kombinasi terapi	.151	9	.200 [*]	.961	9	.811
TBUT_OD_Sebelum	Monoterapi	.297	9	.022	.779	9	.012
	Kombinasi terapi	.192	9	.200 [*]	.917	9	.364
TBUT_OS_Sebelum	Monoterapi	.341	9	.003	.760	9	.007
	Kombinasi terapi	.248	9	.116	.913	9	.338
TBUT_OD_Sesudah	Monoterapi	.135	9	.200 [*]	.945	9	.638
	Kombinasi terapi	.148	9	.200 [*]	.937	9	.555
TBUT_OS_Sesudah	Monoterapi	.237	9	.155	.912	9	.327
	Kombinasi terapi	.336	9	.004	.830	9	.045
Schirmer1OD_Sebelum	Monoterapi	.238	9	.150	.832	9	.047
	Kombinasi terapi	.199	9	.200 [*]	.915	9	.355
Schirmer1OS_Sebelum	Monoterapi	.203	9	.200 [*]	.871	9	.126

	Kombinasi terapi	.144	9	.200*	.917	9	.370
Schirmer1OD_Sesudah	Monoterapi	.228	9	.196	.829	9	.043
	Kombinasi terapi	.167	9	.200*	.939	9	.568
Schirmer1OS_Sesudah	Monoterapi	.220	9	.200*	.884	9	.173
	Kombinasi terapi	.176	9	.200*	.959	9	.792
Schirmer2OD_Sebelum	Monoterapi	.186	9	.200*	.912	9	.327
	Kombinasi terapi	.134	9	.200*	.965	9	.846
Schirmer2OS_Sebelum	Monoterapi	.193	9	.200*	.835	9	.051
	Kombinasi terapi	.198	9	.200*	.916	9	.363
Schirmer2OD_Sesudah	Monoterapi	.233	9	.172	.942	9	.598
	Kombinasi terapi	.203	9	.200*	.891	9	.202
Schirmer2OS_Sesudah	Monoterapi	.167	9	.200*	.971	9	.903
	Kombinasi terapi	.288	9	.030	.806	9	.024
IL6OD_Sebelum	Monoterapi	.158	9	.200*	.963	9	.826
	Kombinasi terapi	.116	9	.200*	.953	9	.724
IL6OS_Sebelum	Monoterapi	.205	9	.200*	.922	9	.406
	Kombinasi terapi	.154	9	.200*	.957	9	.766
IL6OD_Sesudah	Monoterapi	.232	9	.175	.884	9	.172
	Kombinasi terapi	.176	9	.200*	.964	9	.840
IL6OS_Sesudah	Monoterapi	.285	9	.034	.796	9	.018
	Kombinasi terapi	.141	9	.200*	.972	9	.910

a. Lilliefors Significance Correction

*. This is a lower bound of the true significance.

Perlakuan * Gender

Crosstab

Count		Gender		
		Laki-laki	Perempuan	Total
Perlakuan	Monoterapi	6	4	10
	Kombinasi terapi	0	9	9
Total		6	13	19

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	7.892 ^a	1	.005	.011	.008	
Continuity Correction ^b	5.360	1	.021			
Likelihood Ratio	10.239	1	.001	.011	.008	
Fisher's Exact Test				.011	.008	
Linear-by-Linear Association	7.477 ^c	1	.006	.011	.008	.008
N of Valid Cases	19					

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 2.84.

b. Computed only for a 2x2 table

c. The standardized statistic is 2.734.

Tests of Homogeneity of the Odds Ratio

	Chi-Squared	df	Asymp. Sig. (2-sided)
Breslow-Day	.	.	.
Tarone's	.	.	.

Perlakuan * Riwayat_Penyakit

Crosstab

Count		Riwayat_Penyakit		
		Tidak ada	Ada	Total
Perlakuan	Monoterapi	9	1	10
	Kombinasi terapi	8	1	9
Total		17	2	19

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	.006 ^a	1	.937	1.000	.737	
Continuity Correction ^b	.000	1	1.000			
Likelihood Ratio	.006	1	.937	1.000	.737	
Fisher's Exact Test				1.000	.737	
Linear-by-Linear Association	.006 ^c	1	.939	1.000	.737	.526
N of Valid Cases	19					

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .95.

b. Computed only for a 2x2 table

c. The standardized statistic is .077.

T-Test

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
Usia	Equal variances assumed	.062	.807	.281	17	.782	1.67778	5.96212	-10.90119	14.25674
	Equal variances not assumed			.279	15.928	.784	1.67778	6.01188	-11.07152	14.42708
Skor_OSDI_Sebelum	Equal variances assumed	6.828	.018	-1.554	17	.139	-8.69444	5.59606	-20.50110	3.11222
	Equal variances not assumed			-1.494	10.465	.165	-8.69444	5.82075	-21.58619	4.19731
Skor_OSDI_Sesudah	Equal variances assumed	1.032	.324	.555	17	.586	.91389	1.64790	-2.56288	4.39066
	Equal variances not assumed			.566	15.969	.579	.91389	1.61527	-2.51088	4.33866
VisusLog_MAR_OD	Equal variances assumed	.368	.552	-1.364	17	.190	-.18875	.13835	-.48064	.10313
	Equal variances not assumed			-1.330	12.956	.206	-.18875	.14193	-.49548	.11798

VisusLog MAR_OS	Equal variances assumed	6.130	.024	- 1.939	17	.069	-.27914	.14394	-.58283	.02455
	Equal variances not assumed			- 1.861	10.132	.092	-.27914	.15002	-.61282	.05454
TBUT_OD _Sebelum	Equal variances assumed	1.234	.282	-.067	17	.948	-.03333	.49961	-1.08741	1.02075
	Equal variances not assumed			-.067	16.978	.947	-.03333	.49554	-1.07893	1.01226
TBUT_OS_ Sebelum	Equal variances assumed	.181	.676	1.322	17	.204	.55556	.42026	-.33111	1.44222
	Equal variances not assumed			1.327	16.966	.202	.55556	.41870	-.32796	1.43907
TBUT_OD _Sesudah	Equal variances assumed	.545	.470	-.089	17	.931	-.11111	1.25529	-2.75953	2.53731
	Equal variances not assumed			-.090	16.846	.930	-.11111	1.24102	-2.73125	2.50903
TBUT_OS_ Sesudah	Equal variances assumed	1.048	.320	.465	17	.648	.51111	1.09916	-1.80792	2.83015
	Equal variances not assumed			.472	16.564	.643	.51111	1.08275	-1.77788	2.80010
Schirmer1 OD_Sebelu m	Equal variances assumed	.075	.788	-.040	17	.968	-.18889	4.68168	- 10.06638	9.68860
	Equal variances not assumed			-.040	16.140	.969	-.18889	4.71312	- 10.17320	9.79542

Schirmer1 OS_Sebelum	Equal variances assumed	2.682	.120	.495	17	.627	2.14444	4.32791	-6.98665	11.2755 3
	Equal variances not assumed			.483	12.791	.638	2.14444	4.44394	-7.47205	11.7609 4
Schirmer1 OD_Sesudah	Equal variances assumed	1.882	.188	.035	17	.973	.10000	2.88642	-5.98982	6.18982
	Equal variances not assumed			.036	14.319	.972	.10000	2.80258	-5.89838	6.09838
Schirmer1 OS_Sesudah	Equal variances assumed	.060	.809	-.599	17	.557	-2.10000	3.50789	-9.50100	5.30100
	Equal variances not assumed			-.598	16.677	.558	-2.10000	3.51331	-9.52340	5.32340
Schirmer2 OD_Sebelum	Equal variances assumed	.761	.395	.650	17	.524	1.83333	2.82027	-4.11692	7.78358
	Equal variances not assumed			.637	14.068	.534	1.83333	2.87615	-4.33259	7.99926
Schirmer2 OS_Sebelum	Equal variances assumed	5.209	.036	-.265	17	.794	-.96667	3.65219	-8.67212	6.73878
	Equal variances not assumed			-.258	12.947	.800	-.96667	3.74700	-9.06491	7.13158
Schirmer2 OD_Sesudah	Equal variances assumed	.181	.676	.798	17	.436	1.75556	2.20021	-2.88648	6.39760
	Equal variances not assumed			.816	15.562	.427	1.75556	2.15091	-2.81461	6.32572

Schirmer2 OS_Sesudah	Equal variances assumed	.001	.977	.395	17	.697	.68889	1.74245	-2.98736	4.36514
	Equal variances not assumed			.399	16.908	.695	.68889	1.72469	-2.95141	4.32919
IL6OD_Sebelum	Equal variances assumed	1.953	.180	-	17	.163	-15.96934	10.93733	-	7.10641
	Equal variances not assumed			-	12.961	.178	-15.96934	11.22041	-	8.27822
IL6OS_Sebelum	Equal variances assumed	1.258	.278	-	17	.257	-14.04730	11.98540	-	11.23968
	Equal variances not assumed			-	15.166	.265	-14.04730	12.14646	-	11.81764
IL6OD_Sesudah	Equal variances assumed	2.241	.153	-.088	17	.931	-.75490	8.57337	-	17.33333
	Equal variances not assumed			-.089	16.617	.930	-.75490	8.45011	-	17.10460
IL6OS_Sesudah	Equal variances assumed	.498	.490	-.767	17	.454	-6.58496	8.58439	-	11.52651
	Equal variances not assumed			-.790	14.221	.442	-6.58496	8.33092	-	11.25704

Mann-Whitney Test

Ranks

	Perlakuan	N	Mean Rank	Sum of Ranks
Usia	Monoterapi	10	10.75	107.50
	Kombinasi terapi	9	9.17	82.50
	Total	19		
Skor_OSDI_Sebelum	Monoterapi	10	8.75	87.50
	Kombinasi terapi	9	11.39	102.50
	Total	19		
Skor_OSDI_Sesudah	Monoterapi	10	10.30	103.00
	Kombinasi terapi	9	9.67	87.00
	Total	19		
VisusLogMAR_OD	Monoterapi	10	8.40	84.00
	Kombinasi terapi	9	11.78	106.00
	Total	19		
VisusLogMAR_OS	Monoterapi	10	8.15	81.50
	Kombinasi terapi	9	12.06	108.50
	Total	19		
TBUT_OD_Sebelum	Monoterapi	10	10.00	100.00
	Kombinasi terapi	9	10.00	90.00
	Total	19		
TBUT_OS_Sebelum	Monoterapi	10	11.40	114.00
	Kombinasi terapi	9	8.44	76.00
	Total	19		
TBUT_OD_Sesudah	Monoterapi	10	9.80	98.00
	Kombinasi terapi	9	10.22	92.00
	Total	19		
TBUT_OS_Sesudah	Monoterapi	10	10.30	103.00
	Kombinasi terapi	9	9.67	87.00
	Total	19		
OcularStainingOD_Sebelum	Monoterapi	10	10.50	105.00
	Kombinasi terapi	9	9.44	85.00

	Total	19		
OcularStainingOS_Sebelum	Monoterapi	10	9.50	95.00
	Kombinasi terapi	9	10.56	95.00
	Total	19		
OcularStainingOD_Sesudah	Monoterapi	10	10.35	103.50
	Kombinasi terapi	9	9.61	86.50
	Total	19		
OcularStainingOS_Sesudah	Monoterapi	10	9.30	93.00
	Kombinasi terapi	9	10.78	97.00
	Total	19		
Schirmer1OD_Sebelum	Monoterapi	10	9.60	96.00
	Kombinasi terapi	9	10.44	94.00
	Total	19		
Schirmer1OS_Sebelum	Monoterapi	10	10.95	109.50
	Kombinasi terapi	9	8.94	80.50
	Total	19		
Schirmer1OD_Sesudah	Monoterapi	10	9.35	93.50
	Kombinasi terapi	9	10.72	96.50
	Total	19		
Schirmer1OS_Sesudah	Monoterapi	10	8.85	88.50
	Kombinasi terapi	9	11.28	101.50
	Total	19		
Schirmer2OD_Sebelum	Monoterapi	10	10.70	107.00
	Kombinasi terapi	9	9.22	83.00
	Total	19		
Schirmer2OS_Sebelum	Monoterapi	10	10.00	100.00
	Kombinasi terapi	9	10.00	90.00
	Total	19		
Schirmer2OD_Sesudah	Monoterapi	10	10.40	104.00
	Kombinasi terapi	9	9.56	86.00
	Total	19		
Schirmer2OS_Sesudah	Monoterapi	10	10.60	106.00

	Kombinasi terapi	9	9.33	84.00
	Total	19		
IL6OD_Sebelum	Monoterapi	10	8.70	87.00
	Kombinasi terapi	9	11.44	103.00
	Total	19		
IL6OS_Sebelum	Monoterapi	10	8.70	87.00
	Kombinasi terapi	9	11.44	103.00
	Total	19		
IL6OD_Sesudah	Monoterapi	10	9.70	97.00
	Kombinasi terapi	9	10.33	93.00
	Total	19		
IL6OS_Sesudah	Monoterapi	10	8.40	84.00
	Kombinasi terapi	9	11.78	106.00
	Total	19		

T-Test

Paired Samples Statistics

Perlakuan			Mean	N	Std. Deviation	Std. Error Mean
Monoterapi	Pair 1	Skor_OSDI_Sebelum	41.5700	10	6.76253	2.13850
		Skor_OSDI_Sesudah	9.3150	10	4.13788	1.30851
Kombinasi terapi	Pair 1	Skor_OSDI_Sebelum	50.2644	9	16.24103	5.41368
		Skor_OSDI_Sesudah	8.4011	9	2.84115	.94705

Paired Samples Correlations

Perlakuan			N	Correlation	Sig.
Monoterapi	Pair 1	Skor_OSDI_Sebelum & Skor_OSDI_Sesudah	10	.412	.237
Kombinasi terapi	Pair 1	Skor_OSDI_Sebelum & Skor_OSDI_Sesudah	9	.350	.356

Paired Samples Test

Perlakuan			Paired Differences					t	df	Sig. (2-tailed)
			Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
						Lower	Upper			
Monoterapi	Pair 1	Skor_OSDI_Sebelum - Skor_OSDI_Sesudah	3.22550E1	6.30783	1.99471	27.74265	36.76735	16.170	9	.000
Kombinasi terapi	Pair 1	Skor_OSDI_Sebelum - Skor_OSDI_Sesudah	4.18633E1	15.47757	5.15919	29.96622	53.76045	8.114	8	.000

Uji Korelasi Sperman Rank

Paired Samples Statistics

Perlakuan			Mean	N	Std. Deviation	Std. Error Mean
Monoterapi	Pair 1	Skor_OSDI_Sebelum	41.5700	10	6.76253	2.13850
		Skor_OSDI_Sesudah	9.3150	10	4.13788	1.30851
Kombinasi terapi	Pair 1	Skor_OSDI_Sebelum	50.2644	9	16.24103	5.41368
		Skor_OSDI_Sesudah	8.4011	9	2.84115	.94705

Paired Samples Correlations

Perlakuan			N	Correlation	Sig.
Monoterapi	Pair 1	Skor_OSDI_Sebelum & Skor_OSDI_Sesudah	10	.412	.237
Kombinasi terapi	Pair 1	Skor_OSDI_Sebelum & Skor_OSDI_Sesudah	9	.350	.356

Nonparametric Correlations

Perlakuan = Kombinasi

			IL6	Derajat_DE_TB UT
Spearman's rho	IL6	Correlation Coefficient	1.000	.392*
		Sig. (2-tailed)	.	.018
		N	36	36
	Derajat_DE_TBUT	Correlation Coefficient	.392*	1.000
		Sig. (2-tailed)	.018	.
		N	36	36

*. Correlation is significant at the 0.05 level (2-tailed).

a. Perlakuan = Kombinasi

Perlakuan = Monoterapi

			IL6	Derajat_DE_TB UT
Spearman's rho	IL6	Correlation Coefficient	1.000	.271
		Sig. (2-tailed)	.	.091
		N	40	40
	Derajat_DE_TBUT	Correlation Coefficient	.271	1.000
		Sig. (2-tailed)	.091	.
		N	40	40

a. Perlakuan = Monoterapi

Oneway Anova

Test of Homogeneity of Variances

IL6

Perlakuan	Levene Statistic	df1	df2	Sig.
Monoterapi	.626	2	36	.540
Kombinasi	4.433	3	32	.010

ANOVA

IL6

Perlakuan		Sum of Squares	df	Mean Square	F	Sig.
Monoterapi	Between Groups	882.341	3	294.114	.611	.612
	Within Groups	17319.759	36	481.104		
	Total	18202.100	39			
Kombinasi	Between Groups	3858.512	3	1286.171	2.234	.103
	Within Groups	18425.810	32	575.807		
	Total	22284.323	35			

Post Hoc Tests

Multiple Comparisons

Dependent

Variable:IL6

Perlakuan	(I) Derajat_DE_TBU T	(J) Derajat_DE_TBU T	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval		
						Lower Bound	Upper Bound	
						Kombinas i	Tukey HSD	Normal
			Moderate	-19.08849	11.23714	.341	-49.5340	11.3570
			Severe	-25.27547	19.59263	.576	-78.3590	27.8080
	Mild	Normal	-1.83182	12.64699	.999	-36.0971	32.4334	
		Moderate	-20.92031	9.71000	.158	-47.2282	5.3876	
		Severe	-27.10729	18.75851	.482	-77.9309	23.7163	
	Moderate	Normal	19.08849	11.23714	.341	11.3570	49.5340	
		Mild	20.92031	9.71000	.158	-5.3876	47.2282	
		Severe	-6.18698	17.83841	.985	-54.5177	42.1437	

	Severe	Normal	25.27547	19.5926 3	.57 6	- 27.808 0	78.359 0
		Mild	27.10729	18.7585 1	.48 2	- 23.716 3	77.930 9
		Moderate	6.18698	17.8384 1	.98 5	- 42.143 7	54.517 7
Games	Normal	Mild	1.83182	8.78496	.99 7	- 25.655 8	29.319 5
-Howell		Moderate	- 19.08849	9.96746	.26 7	- 48.122 8	9.9458
		Severe	- 25.27547	9.64999	.17 1	- 63.505 4	12.954 4
	Mild	Normal	-1.83182	8.78496	.99 7	- 29.319 5	25.655 8
		Moderate	- 20.92031	8.13571	.07 2	- 43.243 5	1.4028
		Severe	- 27.10729	7.74350	.14 4	- 71.812 1	17.597 5
	Moderate	Normal	19.08849	9.96746	.26 7	-9.9458	48.122 8
		Mild	20.92031	8.13571	.07 2	-1.4028	43.243 5
		Severe	-6.18698	9.06292	.89 9	- 41.618 5	29.244 6

Severe	Normal	25.27547	9.64999	.17 1	- 12.954 4	63.505 4
	Mild	27.10729	7.74350	.14 4	- 17.597 5	71.812 1
	Moderate	6.18698	9.06292	.89 9	- 29.244 6	41.618 5

Mann-Whitney Test

	Perlakuan	N	Mean Rank	Sum of Ranks
Derajat_DE_TBUT_Sebelum	Monoterapi	20	23.90	478.00
	Kombinasi terapi	18	14.61	263.00
	Total	38		
Derajat_DE_TBUT_Sesudah	Monoterapi	20	23.02	460.50
	Kombinasi terapi	18	15.58	280.50
	Total	38		

	Derajat_DE_TBUT _Sebelum	Derajat_DE_TBUT _Sesudah
Mann-Whitney U	92.000	109.500
Wilcoxon W	263.000	280.500
Z	-3.078	-2.270
Asymp. Sig. (2-tailed)	.002	.023
Exact Sig. [2*(1-tailed Sig.)]	.009 ^a	.038 ^a

a. Not corrected for ties.

b. Grouping Variable: Perlakuan

Mann-Whitney Test

Ranks				
	Perlakuan	N	Mean Rank	Sum of Ranks
Derajat_DE_OSDI_Sebelum	Monoterapi	10	10.50	105.00
	Kombinasi terapi	9	9.44	85.00
	Total	19		
Derajat_DE_OSDI_Sesudah	Monoterapi	10	11.35	113.50
	Kombinasi terapi	9	8.50	76.50
	Total	19		

Test Statistics ^b		
	Derajat_DE_OSDI _Sebelum	Derajat_DE_OSDI _Sesudah
Mann-Whitney U	40.000	31.500
Wilcoxon W	85.000	76.500
Z	-1.054	-1.743
Asymp. Sig. (2-tailed)	.292	.081
Exact Sig. [2*(1-tailed Sig.)]	.720 ^a	.278 ^a

a. Not corrected for ties.

b. Grouping Variable: Perlakuan

T-Test

Group Statistics					
	Perlakuan	N	Mean	Std. Deviation	Std. Error Mean
Schirmer1_Sesudah	Monoterapi	20	17.5000	7.40199	1.65514
	Kombinasi terapi	18	18.5000	6.25206	1.47362

Independent Samples Test

	Levene's Test for Equality of Variances		t-test for Equality of Means						
	F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
								Lower	Upper
Schirmer1_Sesudah	.601	.443	-.447	36	.657	-1.00000	2.23622	-5.53527	3.53527
Equal variances assumed									
Schirmer1_Sesudah			-.451	35.870	.655	-1.00000	2.21609	-5.49500	3.49500
Equal variances not assumed									

Mann-Whitney Test

Ranks

Perlakuan	N	Mean Rank	Sum of Ranks
Schirmer1_Sebelum Monoterapi	20	20.22	404.50
Schirmer1_Sebelum Kombinasi terapi	18	18.69	336.50
Total	38		

Test Statistics^b

	Schirmer1_Sebelum
Mann-Whitney U	165.500
Wilcoxon W	336.500
Z	-.425
Asymp. Sig. (2-tailed)	.671
Exact Sig. [2*(1-tailed Sig.)]	.675 ^a

a. Not corrected for ties.

b. Grouping Variable: Perlakuan

Mann-Whitney Test

Ranks

	Perlakuan	N	Mean Rank	Sum of Ranks
OcularStaining_Sebelum	Monoterapi	20	19.50	390.00
	Kombinasi terapi	18	19.50	351.00
	Total	38		
OcularStaining_Sesudah	Monoterapi	20	19.12	382.50
	Kombinasi terapi	18	19.92	358.50
	Total	38		

Test Statistics^b

	OcularStaining_Se belum	OcularStaining_Se sudah
Mann-Whitney U	180.000	172.500
Wilcoxon W	351.000	382.500
Z	.000	-.286
Asymp. Sig. (2-tailed)	1.000	.775
Exact Sig. [2*(1-tailed Sig.)]	1.000 ^a	.828 ^a

a. Not corrected for ties.

b. Grouping Variable: Perlakuan

T-Test

Group Statistics

	Perlakuan	N	Mean	Std. Deviation	Std. Error Mean
TBUT_Sesudah	Monoterapi	20	8.2000	2.76444	.61815
	Kombinasi terapi	18	8.0000	2.16930	.51131

Independent Samples Test

	Levene's Test for Equality of Variances		t-test for Equality of Means						
	F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
								Lower	Upper
TBUT_Sesudah Equal variances assumed	1.653	.207	.246	36	.807	.20000	.81259	-1.44802	1.84802
Equal variances not assumed			.249	35.382	.805	.20000	.80221	-1.42795	1.82795

Mann-Whitney Test

Ranks

Perlakuan	N	Mean Rank	Sum of Ranks
TBUT_Sebelum Monoterapi	20	20.65	413.00
Kombinasi terapi	18	18.22	328.00
Total	38		

Test Statistics^b

	TBUT_Sebelum
Mann-Whitney U	157.000
Wilcoxon W	328.000
Z	-.702
Asymp. Sig. (2-tailed)	.483
Exact Sig. [2*(1-tailed Sig.)]	.515 ^a

a. Not corrected for ties.

b. Grouping Variable: Perlakuan

T-Test

Group Statistics

	Perlakuan	N	Mean	Std. Deviation	Std. Error Mean
Skor_OSDI_Sesudah	Monoterapi	10	9.3150	4.13788	1.30851
	Kombinasi terapi	9	8.4011	2.84115	.94705

Independent Samples Test

	Levene's Test for Equality of Variances		t-test for Equality of Means						
	F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
								Lower	Upper
Skor_OSDI_Sesudah Equal variances assumed	1.032	.324	.555	17	.586	.91389	1.64790	-2.56288	4.39066
Skor_OSDI_Sesudah Equal variances not assumed			.566	15.969	.579	.91389	1.61527	-2.51088	4.33866

NPar Tests

Mann-Whitney Test

Ranks

	Perlakuan	N	Mean Rank	Sum of Ranks
Skor_OSDI_Sebelum	Monoterapi	10	8.75	87.50
	Kombinasi terapi	9	11.39	102.50
	Total	19		

Test Statistics^b

	Skor_OSDI_Sebelum
Mann-Whitney U	32.500
Wilcoxon W	87.500
Z	-1.022
Asymp. Sig. (2-tailed)	.307
Exact Sig. [2*(1-tailed Sig.)]	.315 ^a

a. Not corrected for ties.

b. Grouping Variable: Perlakuan

Derajat_DE_TBUT_Sesudah

Case Processing Summary

	Derajat_DE_TBUT_Sesudah	Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
IL6_Sesudah	Normal	7	100.0%	0	.0%	7	100.0%
	Mild	20	100.0%	0	.0%	20	100.0%
	Moderate	11	100.0%	0	.0%	11	100.0%

Descriptives

Derajat_DE_TBUT_Sesudah			Statistic	Std. Error	
IL6_Sesudah	Normal	Mean	72.6847	6.53275	
		95% Confidence Interval for Mean	Lower Bound		56.6997
			Upper Bound		88.6698
		5% Trimmed Mean	72.1720		
		Median	69.2055		
		Variance	298.737		
		Std. Deviation	1.72840E1		
		Minimum	52.23		
		Maximum	102.36		
		Range	50.13		
		Interquartile Range	25.45		
		Skewness	.721		.794
		Kurtosis	-.069		1.587
		Mild			Mean
95% Confidence Interval for Mean	Lower Bound			63.8191	
	Upper Bound			81.5291	
5% Trimmed Mean	71.4758				
Median	68.3932				
Variance	357.979				
Std. Deviation	1.89203E1				
Minimum	43.49				
Maximum	123.42				
Range	79.93				
Interquartile Range	29.53				
Skewness	1.036			.512	
Kurtosis	1.265			.992	
Moderate				Mean	68.4357
		Lower Bound	55.5599		

95% Confidence Interval for Mean	Upper Bound	81.3115	
5% Trimmed Mean		67.9078	
Median		66.8832	
Variance		367.329	
Std. Deviation		1.91658E1	
Minimum		43.87	
Maximum		102.50	
Range		58.63	
Interquartile Range		26.39	
Skewness		.562	.661
Kurtosis		-.306	1.279

IL6_Sesudah

Oneway

Test of Homogeneity of Variances

IL6_Sesudah

Levene Statistic	df1	df2	Sig.
.012	2	35	.988

ANOVA

IL6_Sesudah	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	140.584	2	70.292	.201	.819
Within Groups	12267.313	35	350.495		
Total	12407.896	37			

Post Hoc Tests

Multiple Comparisons

Dependent Variable: IL6_Sesudah

	(I)	(J)	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
						Lower Bound	Upper Bound
Tukey HSD	Normal	Mild	.01065	8.22164	1.000	-20.1100	20.1313
		Moderate	4.24901	9.05173	.886	-17.9031	26.4011
	Mild	Normal	-.01065	8.22164	1.000	-20.1313	20.1100
		Moderate	4.23836	7.02765	.819	-12.9602	21.4370
	Moderate	Normal	-4.24901	9.05173	.886	-26.4011	17.9031
		Mild	-4.23836	7.02765	.819	-21.4370	12.9602
Game s- Howell	Normal	Mild	.01065	7.78304	1.000	-20.8879	20.9093
		Moderate	4.24901	8.72183	.878	-18.5894	27.0874
	Mild	Normal	-.01065	7.78304	1.000	-20.9093	20.8879
		Moderate	4.23836	7.16188	.826	-13.8469	22.3236
	Moderate	Normal	-4.24901	8.72183	.878	-27.0874	18.5894
		Mild	-4.23836	7.16188	.826	-22.3236	13.8469

Homogeneous Subsets

IL6_Sesudah

Derajat_DE_TBUT_Sesudah	N	Subset for alpha = 0.05
		1
Tukey HSD ^a Moderate	11	68.4357
Mild	20	72.6741
Normal	7	72.6847
Sig.		.861

Means for groups in homogeneous subsets are displayed.

a. Uses Harmonic Mean Sample Size = 10.572.

T-Test

Group Statistics

Derajat_DE_TBUT_Sebelum		N	Mean	Std. Deviation	Std. Error Mean
IL6_Sebelum	Moderate	24	92.4609	28.53733	5.82516
	Severe	14	85.0980	17.88576	4.78017

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
IL6_Sebelum	Equal variances assumed	5.864	.021	.868	36	.391	7.36290	8.47986	-9.83504	24.56084
	Equal variances not assumed			.977	35.736	.335	7.36290	7.53542	-7.92356	22.64936

Oneway

Test of Homogeneity of Variances

IL6_Sebelum

Levene Statistic	df1	df2	Sig.
5.864	1	36	.021

ANOVA

IL6_Sebelum					
	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	479.351	1	479.351	.754	.391
Within Groups	22889.433	36	635.818		
Total	23368.784	37			

LAMPIRAN 6. CURRICULUM VITAE

CURRICULUM VITAE

1. Data Pribadi

Nama : Desti Priani
Tempat, tanggal Lahir: Raha, 14 Desember 1991
Jenis Kelamin : Perempuan
Kewarganegaraan : Warga Negara Indonesia
Agama : Islam
Status Pernikahan : Menikah
Alamat : Jl. Gatot Subroto Baubau
No. HP : 081243426387
Email : desti.priani@gmail.com



2. Riwayat Pendidikan:

NO.	JENJANG PENDIDIKAN	INSTITUSI	TEMPAT	TAHUN
1.	SD	SDN 13 Baruga	Kendari	1997 - 2003
2.	SLTP	SLTP Negeri 9	Kendari	2003 - 2006
3.	SMU	SMU Negeri 1	Kendari	2006 - 2009
4.	S1	FK Universitas Hasanuddin	Makassar	2009 – 2012
5.	Profesi	Universitas Hasanuddin	Makassar	2012-2014
6.	PPDS	Bagian Ilmu Kesehatan Mata FK UNHAS	Makassar	Juli 2019 - Sekarang

3. Riwayat pekerjaan

NO.	INSTANSI	TEMPAT	KEDUDUKAN	PERIODE
1.	Puskesmas Batauga	Buton Selatan, Sulawesi Tenggara	Dokter Umum	2016-2017
2.	RS Siloam Buton	Baubau, Sulawesi Tenggara	Dokter Umum & Casemix	2017-2019

